Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda + enzalutamide + ADT in metastatic hormone-sensitive prostate cancer
CTR20210546Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in prostate cancer (PCa), sponsored by Merck & Co.. Started Mar 2021; status: terminated.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20210546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210546.